文献速递肾癌与肾肿瘤

纳武利尤单抗联合立体定向体部放疗治疗经治转移性肾细胞癌:II期NIVES研究结果

Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.
PubMed 文献 · Eur Urol · 2021-10-01

NIVES是一项II期单臂多中心研究,评估纳武利尤单抗联合SBRT在经抗血管生成治疗进展的mRCC二、三线患者中的疗效与安全性。未发现联合方案较纳武利尤单抗单药有额外获益的证据,但安全性可控,照射病灶反应良好,建议在寡转移或寡进展患者中进一步评估。

要点

  • 纳武利尤单抗联合SBRT在经治mRCC中ORR为17%,未达预设40%的疗效目标。
  • 中位PFS 5.6个月,中位OS 20个月,中位缓解持续时间14个月。
  • 联合方案安全性可控,未出现新的安全性信号,照射病灶反应良好。

核心结论

  • 未发现足够证据表明纳武利尤单抗联合SBRT在经治mRCC中提供额外获益。
  • 该联合方案安全性可控,照射病灶反应良好,建议在寡转移或寡进展患者中进一步评估。

研究设计与样本

  • 患者接受SBRT(10 Gy分3次,自纳武利尤单抗首次输注起7天内)联合纳武利尤单抗(240 mg每14天,6个月后对缓解者480 mg每4周)。

主要发现

  • ORR为17%,DCR为55%。
  • 中位PFS为5.6个月(95%CI 2.9-7.1),中位OS为20个月(95%CI 17-未达到)。
  • 随访1.5年后23例患者死亡,中位至缓解时间2.8个月,中位缓解持续时间14个月。
  • 未出现新的安全性问题。

关键数值与推荐

  • 研究假设ORR从历史对照的25%提高至40%,实际ORR为17%。
  • SBRT剂量为10 Gy分3次。
  • 纳武利尤单抗初始剂量240 mg每14天,6个月后缓解者480 mg每4周。

临床怎么用

  • 不推荐在未经选择的经治mRCC患者中常规使用纳武利尤单抗联合SBRT。
  • 可考虑在寡转移或寡进展患者中进一步评估该联合策略。
  • 联合方案安全性可控,照射病灶可观察到良好反应。

局限性

  • ORR未达预设目标,结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nivolumab showed an overall survival (OS) benefit in pretreated metastatic renal cell carcinoma (mRCC). The role of stereotactic body radiotherapy (SBRT) in mRCC remains to be defined. OBJECTIVE: Our aim was to evaluate the efficacy and safety of SBRT in combination with nivolumab in second- and third-line mRCC patients. DESIGN, SETTING, AND PARTICIPANTS: The NIVES study was a phase II, single-arm, multicenter trial in patients with mRCC with measurable metastatic sites who progressed after antiangiogenic therapy, of whom at least one was suitable for SBRT. INTERVENTION: The patients received SBRT to a lesion at a dose of 10 Gy in three fractions for 7 d from the first infusion of nivolumab. Nivolumab was given at an initial dose of 240 mg every 14 d for 6 mo and then 480 mg q4-weekly in responding patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We hypothesized that nivolumab plus SBRT improves the objective response rate (ORR) compared with nivolumab alone from 25% (derived from historical controls) to 40%. Secondary endpoints were progression-free survival (PFS), OS, disease control rate (DCR) of irradiated and nonirradiated metastases, and safety. RESULTS AND LIMITATIONS: Sixty-nine patients were enrolled from July 2017 to March 2019. The ORR was 17% and the DCR was 55%. The median PFS was 5.6 mo (95% confidence interval [CI], 2.9-7.1) and median OS 20 mo (95% CI, 17-not reached). After 1.5 yr of follow-up, 23 patients died. The median time to treatment response was 2.8 mo and median duration of response was 14 mo. No new safety concerns arose. CONCLUSIONS: We did not find sufficient evidence to suggest that nivolumab in combination with SBRT provides an added benefit in pretreated mRCC patients; it should however be evaluated in patients with oligometastatic or oligoprogressive disease. PATIENT SUMMARY: Nivolumab in combination with stereotactic body radiotherapy does not provide evidence of increased outcomes in metastatic renal cell carcinoma patients. However this approach was safe and showed a good response of the irradiated lesions.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Masini C, Iotti C, De Giorgi U, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2021. PMID: 34602312. doi:10.1016/j.eururo.2021.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。